Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program

Identification of prognostic factors for plerixafor‐based hematopoietic stem cell mobilization

“…It was suggested that plerixafor might be used in combination with granulocyte-colony stimulating factor (G-CSF) in patients with myeloma or lymphoma in whom an initial mobilization regimen either was predicted to fail or had failed already. The reports on the outcomes of this program revealed that a very reproducible proportion of patients were mobilized successfully with plerixafor (63-75%) [2][3][4][5][6]. However, it was clear that, in a subset of patients, mobilization could not be rescued successfully with plerixafor.…”

Plerixafor for Autologous Stem-Cell Mobilization and Transplantation for Patients in Ontario

“…The remaining seven studies reported results from 13 European countries (Austria, Belgium, Croatia, Czech Republic, France, Germany, Hungary, Italy, Poland, Portugal, Slovakia, Spain, and the United Kingdom) that enrolled patients in a compassionate use program that provided plerixafor to patients who had failed prior mobilization attempts [17][18][19][21][22][23]26 . In a subgroup analysis from the European Consortium of Stem Cell Mobilization, Hubel et al 22 reported results for 580 patients enrolled in European cups.…”

“…In all studies, the mobilization regimen was consistent with the regimen that would be used in Ontario clinical practice. Eight of the studies 17,18,[20][21][22][23]26,28 included patients enrolled in a European compassionate-use program (cup) for patients who had previously failed conventional mobilization attempts. The inclusion and exclusion criteria were fully described for all those studies.…”

“…Twenty-two studies assessing the efficacy and safety of plerixafor for autologous stem-cell mobilization and transplantation were retained: two randomized controlled trials (rcts) 6,7 , five nonrandomized controlled trials [8][9][10][11][12] , three retrospective cohort studies with a contemporaneous control arm [13][14][15] , and twelve single-arm studies [16][17][18][19][20][21][22][23][24][25][26][27] .…”

“…The twelve single-arm trials [16][17][18][19][20][21][22][23][24][25][26][27] were included in the review to inform recommendations both for patients failing mobilization before asct and for patients failing a prior mobilization attempt. In all those studies, the patients were fully described and were representative of the population of interest.…”